Difructose anhydride III enhances bioavailability of water-insoluble iron in anemic Vietnamese women.
Difructose anhydride III (DFAIII) is an indigestible disaccharide and has been shown to enhance iron absorption in animal studies; however, the effect has not been investigated in anemic subjects. We investigated the efficacy of co-administration of DFAIII with water-insoluble iron in the treatment of iron deficiency anemia in Vietnamese women. One hundred sixty-eight moderately anemic women (80 g/L<hemoglobin (Hb)<120 g/L) participated in a double-blinded, placebo-controlled study with daily supplementation of iron for 6 mo. The volunteers were randomly assigned into four groups, i.e., Group A: received 15 mg Fe as ferric pyrophosphate; Group B: received 15 mg Fe as ferric pyrophosphate and 1.25 g DFAIII; Group C: received 15 mg Fe as ferrous sulfate; Group D: received a placebo. Hb and iron status were measured at baseline and after 2, 4 and 6 mo of intervention. The ratio of transferrin receptor to ferritin was used to estimate stored and functional body iron (BI). One hundred sixteen (69.0%) women completed the trial. After 6 mo, mean (+/-SE) Hb concentration was higher in Group A (121.6+/-1.7 g/L), Group B (126.4+/-1.5 g/L) and Group C (126.8+/-1.6 g/L) compared to Group D (107.0+/-1.7 g/L, p<0.0001). Mean change in BI was twofold greater in Group B (5.0+/-0.5 mg/kg) than that in Group A (2.5+/-0.6 mg/kg, p=0.008). The percentage of anemia was significantly reduced in Group B (18.8%) compared to Group D (95.8%, p<0.0001) and Group A (39.1%, p=0.033). Co-administration of DFAIII enhances Hb concentration and iron stores more than single administration of water-insoluble iron in anemic Vietnamese women.
Nakamori
Masayo
M
Department of Nutrition and Food Science, Ochanomizu University, Tokyo, Japan. masana97@hotmail.com
Hien
Vu Thi Thu
VT
Khan
Nguyen Cong
NC
Lam
Nguyen Thi
NT
Dung
Nguyen Tri
NT
Uotsu
Nobuo
N
Shiomi
Takuya
T
Okuhara
Yasuhide
Y
Kise
Mitsuo
M
Shigematsu
Norihiro
N
Yamamoto
Shigeru
S
D000277:Adjuvants, Pharmaceutic / Q000627:therapeutic use*; D000328:Adult; D000465:Algorithms; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D001682:Biological Availability; D011756:Diphosphates / Q000008:administration & dosage; D004187:Disaccharides / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008875:Middle Aged; D009752:Nutritional Status; D011990:Receptors, Transferrin / Q000097:blood; D012720:Severity of Illness Index; D012995:Solubility; D013997:Time Factors; D014168:Transferrin / Q000032:analysis; D014744:Vietnam; D055815:Young Adult
D000277:Adjuvants, Pharmaceutic; D011756:Diphosphates; D004187:Disaccharides; D005296:Ferrous Compounds; D006454:Hemoglobins; D011990:Receptors, Transferrin; D014168:Transferrin; C020748:ferrous sulfate; C087758:difructose anhydride III; D007501:Iron; C049051:ferric pyrophosphate